In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer

Overview of attention for article published in Journal of Inflammation Research, September 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 6 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 1,761 followers.

In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal ... https://t.co/nMknXCi9by

27 Dec 2021

Reply Repost Favourite

In vivo pharmacokinetic and anticancer studies of hh-n25, a selective inhibitor of topoisomerase i, and hormonal signaling for treating breast cancer doi:10.2147/JIR.S329401 https://t.co/cWfvHhuYzg

10 Dec 2021

Reply Repost Favourite

In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer https://t.co/G2hc0Urcas

23 Sep 2021

Reply Repost Favourite

Anticancer studies of HH-N25 for treating breast cancer | JIR - Dove Medical Press https://t.co/MzawNVZ8nw

22 Sep 2021

Reply Repost Favourite

Anticancer studies of HH-N25 for treating breast cancer | JIR - Dove Medical Press https://t.co/0Dj214Qk7A

22 Sep 2021

Reply Repost Favourite

Dove Medical Press

Article Metrics

In vivo Pharmacokinetic and Anticancer Studies of HH-N25, a Selective Inhibitor of Topoisomerase I, and Hormonal Signaling for Treating Breast Cancer

About this Attention Score

Mentioned by

Citations

Readers on